# Clinical Trials Data KRAS - Document 33

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with a KRAS gene mutation would not automatically be excluded from participation. The criteria primarily focus on having a diagnosis of refractory non-small cell lung cancer, having received sorafenib tosylate on the specified protocol (ECOG-E2501), and having available blood specimens. There is no mention of specific genetic mutations like KRAS being a factor for eligibility or exclusion.  
  
Thus, as long as the patient meets the other specified criteria, the presence of a KRAS gene mutation would not affect their eligibility for this clinical trial. However, it is always recommended to consult with the trial coordinators or investigators to confirm eligibility based on all specific medical details.